Meinhard is a MedTech industry executive and entrepreneur with more than 25 years broad international experience ranging from global General-, Operations-, Marketing- and Innovation Management. He is currently founder and CEO at mt:onyx, an established Swiss-based service organization providing business partnering and business development in the area of Life Sciences, Diagnostics and Medical Devices industry. His activities include investments in start-ups with active board engagement and management support, consulting investors on identification of opportunities in the global MedTech industry and helping start-ups to establish business partnerships. Prior to this, he worked as an executive at Straumann AG (CH), responsible for the world-wide “Digitalization” of the Dental industry. Between 1998 and 2008, Meinhard was at Roche Diagnostics where he held various global senior leadership roles in Diabetes Care, Decentralized Solutions and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry. Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, programme and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at several healthcare/diagnostic companies in UK, Sweden and Switzerland.
Geoffrey has an entrepreneurial career that started in 1982 when Geoffrey founded a number of companies in the media sector backed by The Abingdon Management Company Limited (Abingdon). In 1988, he joined the board of Abingdon as CEO to manage the Company’s portfolio of media and technology investments, and subsequently became sole owner having acquired Abingdon from its institutional shareholders. Abingdon had a number of quoted and unquoted investments. In 1998 he launched Premium TV (PTV) securing a contractual joint venture with Eurosport to create “British Eurosport”. Later that year PTV was acquired by NTL (now Virgin Media). As CEO of PTV Geoffrey developed the largest integrated broadband and internet sports broadcasting platform in the world at that time. Over the past ten years Geoffrey has developed Oncimmune Limited, serving as its Executive Chairman, CEO and now Vice Chairman. Geoffrey is also a senior research fellow at the International Prevention Research Institute. His personal commitment to cancer detection can be traced to his father, the first medical oncologist in the United Kingdom.
Dr Adam M Hill MB PhD is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last 2 decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Additionally, over the last 5 years Adam has been an early stage investor in, and advisor to, a number of health technology start-ups. Currently, Adam is both a Visiting Professor in Global Health Innovation at Imperial College London, and sits on the Value Creation Committee of Imperial College Health Partners.
Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers. Adam has built a portfolio of over 100 academic peer-reviewed, policy and popular-media publications, including contributions to the Financial Times, BBC, Business Insider, The Telegraph, Men’s Health (US) and Men’s Fitness.
Dr Jett’s research interests focus on the screening and early detection of lung cancer. His research has been funded by the National Cancer Institute and he was part of a research team that documented how CT screening can be an effective tool to detect lung cancer early in high-risk patients. Dr Jett is board certified in Internal Medicine and Pulmonary Medicine. He completed his medical degree at the University of Missouri, Columbia. He completed a residency in Internal Medicine and a fellowship in Pulmonary Diseases at Mayo Graduate School of Medicine, and a research fellowship at the National Cancer Institute. He is on the Scientific Advisory Committee for the American Lung Association and was an External Review Chair for the Terry Fox Research Institute, Lung Cancer Grant Review. Dr Jett has served in journal review for many medical publications, including the American Journal of Respiratory and Critical Care Medicine, Annals of Internal Medicine, Cancer, Chest, International Journal of Cancer, Lung Cancer and The New England Journal of Medicine. He has been on the Editorial Boards of CHEST, THORAX and American Journal of Respiratory and Critical Care Medicine Dr. Jett was editor-in-chief of the Journal of Thoracic Oncology from 2006 to 2012 and was Co-Editor from 2008-2017 of the Lung Cancer Section of the electronic textbook “Up-To-Date”.
Dr Navani qualified in Medicine from Cambridge and UCL in 2000 with distinction and several University prizes. He trained in Respiratory Medicine at the Brompton and Hammersmith Hospitals before winning a Medical Research Council Fellowship in 2008 and completing his PhD at UCL in 2011. He has also completed an MSc in Clinical Trials at the London School of Hygiene and Tropical Medicine. Dr Navani is a Consultant in Thoracic Medicine at University College London Hospital. He specialises in respiratory disorders and has particular expertise in patients with lung cancer and in bronchoscopy. He runs the regional Endobronchial Ultrasound (EBUS) service at UCLH and has performed over 3,000 procedures. Dr Navani is clinical lead for lung cancer services at UCLH and co-chairs the specialist lung cancer weekly MDT. Dr Navani runs several clinical trials on the diagnosis and staging of lung disease and bronchoscopic techniques. He holds an honorary position at the Medical Research Council Clinical Trials Unit and is also a member of the UCLH early lung cancer detection and surveillance programme. Dr Navani has authored over 35 peer-reviewed publications, including leading articles on endobronchial ultrasound. He is the co-author of a textbook on respiratory disorders. He is an invited member of the British Thoracic Society guideline development group for bronchoscopy and is on the interventional procedures specialist advisory group. He is a member of the National Cancer Research Institute lung cancer clinical studies group. He sits on the lung cancer board of London Cancer and is a peer reviewer for many journals including PLOSone and Thorax.
Andrew is a Chartered Accountant and registered auditor. Andrew qualified as a chartered accountant with Stoy Hayward (now BDO), following which he gained an MBA from Henley Management College. Andrew has spent many years at executive level involved with the growth and success of early stage technology businesses. Andrew is a director of Wisteria Chartered Accountants, a firm he founded in 2002 and he has, since 2003, been involved in a variety of capacities with Oncimmune including as accountant, company secretary and shareholder.
Dan served as President and CEO of Oncimmune USA since June 2009 until the acquisition of the US laboratory operations in October 2013. He is currently the President and CEO of Gyros, AB, a global immunoassay instrument Company. Prior to joining Oncimmune USA, Dan was the CEO of two successful companies, Cellomics and Assay Designs, each of which were acquired, by Fisher Scientific and Enzo Biochem respectively. He had a 20 year progressive career with DuPont, and then served as Commercial SVP of NEN Life Sciences, a spinout Company of DuPont, which was sold to PerkinElmer. Dan also served as global commercial VP there until joining Cellomics as CEO in 2003. He also serves as Chairman of the Board of Optra Systems, an India-based healthcare IT Company.
Dr Murray studied Applied Biology at Nottingham Trent University before reading for a PhD in Pharmaceutical Sciences at the University of Nottingham. The focus of Dr Murray’s PhD studies, was the development of monoclonal antibodies for diagnosis of cancer. She later worked on the development of peptide mimetics for purification of monoclonal antibodies and antibody fragments and then spent three years developing radioimmunoconjugates for diagnosis and treatment of bladder cancer. During this postdoctoral research position, Dr Murray was awarded a travel fellowship by the European Association for Cancer Research which allowed her to spend a period of training at the Paul Scherrer Institute in Switzerland where she worked on the development of techniques for conjugating rhenium-188 to biological molecules such as antibodies. Dr Murray has published over 40 papers in peer reviewed journals and has written several book chapters and invited reviews. She has presented her work at numerous national and international conferences. When Dr Murray joined Oncimmune Limited in 2004 as Senior Director of Assay Development she was one of the Company’s first employees. Since then she has been involved with the EarlyCDT® platform through all of its stages of development and validation and has provided critical technical leadership.
Dr. Laura J. Peek earned a Ph.D. with Honors in Pharmaceutical Chemistry from The University of Kansas(KU) in 2006 and was recognized with a Schering-Plough Science and Innovation Award for her doctoral research, which focused on characterizing the stability of biopharmaceutics, optimizing their formulation for maximum stability and further evaluating their stability on surfaces of aluminum salt adjuvants, polymeric nanoparticles and microparticles. Throughout her doctoral studies, Dr. Peek received the Madison & Lila Self Graduate Fellowship, a competitive four-year multi-disciplinary doctoral fellowship at KU that provides extensive professional development training in preparation for future leadership roles. Dr. Peek went on to complete post-doctoral training at KU working on projects related to polymeric particle technology and drug delivery. In 2007 she joined Oncimmune USA LLC as the second employee of the newly-formed US subsidiary and established the clinical laboratory operations from the ground up, including transfer of technology from the parent company in the UK, development of a comprehensive quality system and oversight of the laboratory’s regulatory compliance. Dr. Peek also played an integral role in the validation, scale-up and commercial launch of EarlyCDT®-Lung and managed a prospective clinical audit of outcomes for 1600 patients, the results of which were published in the journal Lung Cancer. Dr. Peek is passionate about helping others and in her spare time enjoys mentoring students about various career opportunities that exist in science. Dr. Peek currently serves on the Board of Trustees for the Self Graduate Fellowship and is serving an elected 4-year term on the Board of Governors for the Society of Self Fellows.
Maarten is a seasoned international business executive in laboratory diagnostics with a proven success record in the EMEA and APAC regions. He has worked in different fields including public health laboratory, manufacturing, sales, marketing and general management. As Chief Commercial Officer, Asia Pacific, he leads the sales process in the region and is responsible for targeting out-license opportunities. He has over two decades of relevant experience in laboratory diagnostics with particular expertise in the Asia region. Most recently Maarten was General Manager and Senior Director Molecular Sales EMEIA at Luminex Corporation since 2013 and prior to that he was General Manager and Commercial Director Asia Pacific at Abbott Molecular from 2009. He also worked as Sales Manager NEMEA at AcroMetrix Europe BV between 2007-2009.
Delia (DeeDee) Rivas is Vice President, Americas Sales of Oncimmune which she joined in December 2016. Previously DeeDee served as Vice President of Sales at Mid America Clinical Laboratories, an Indianapolis, Indiana Quest Diagnostics joint venture. DeeDee has a wealth of experience to bring to Oncimmune having held several roles within the diagnostic laboratory industry over the last 17 years, encompassing many areas of healthcare including test launches, growth and team building. DeeDee is also IASSC Certified Lean Six Sigma Black Belt.
Dr Mike Fisher has 20 years’ experience of life sciences business development, commercialisation, project management and government relations. He has worked in both the public and private sectors, focusing on the diagnostics industry for the past 9 years. As Commercial Director, Mike is responsible for driving adoption of Oncimmune’s EarlyCDT-Lung test in the UK and Europe, building Oncimmune’s activities in companion diagnostics and commercial planning for the company’s next generation of products. Mike joined Oncimmune from Abcodia, where he was Director of Strategic Alliances. Prior to this he was Business Development Director for Bio Nano Consulting and between 2005 and 2008, Mike was the UK government’s Life Sciences Industry Advisor for North America, based in Cambridge MA, where he liaised between US corporates and the Department of Health, NICE and MHRA. Before working in the US, Mike held project management and economic development roles for both public bodies and consultancies. He was a founder of the Northwest Genetics Knowledge Park and has led numerous successful grant funded projects from ERDF, FP7, Horizon 2020 and Innovate UK.
Shane is a commercial leader with more than 15 years’ experience within market access, reimbursement and sales management. He has extensive knowledge of the US market and a proven track record in sales force development, training, government accounts, Managed Care Organisations and laboratory contracting. Shane has successfully led the development and execution of market access and payor strategies to obtain coverage and value based reimbursement for multiple organisations, and is highly experienced in molecular diagnostic contracting with national, regional and local health plans, as well as reference laboratories and hospital systems of all sizes. In addition, he has successfully managed several high dose immunotherapy centres (Oncology). His experience also covers recruitment, managing and developing field based talent, conducting coaching, training, and providing directional leadership for both diagnostic and therapeutic products. Most recently, Shane was Vice President, Market Access & Reimbursement, Lineagen, Inc. in Salt Lake City, UT where he focused on coverage and value-based reimbursement for Lineagen’s portfolio. Prior to Lineagen, Shane led Market Access, Payer Markets & Reimbursement for KEW Group to establish coverage and value-based reimbursement for their proprietary next-generation sequencing solid tumor gene test. Earlier in his career, Shane held multiple roles with Prometheus Laboratories, acquired by Nestle Health Science, and Novartis Pharmaceuticals Corp.
Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).
These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.
By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.